**Interrelationship between Vitamin D and Calcium in Obesity and Its Comorbid Conditions**

Iskandar Azmy Harahap $^{1,*}$, Jean-François Landrier $^{2}$ and Joanna Suliburska $^{1,*}$

$^{1}$ Department of Human Nutrition and Dietetics, Poznan University of Life Sciences, Wojska Polskiego St. 31, 60-624 Poznan, Poland; iskandar.harahap@up.poznan.pl

$^{2}$ Aix Marseille University, C2VN, INRAE, INSERM, 13385 Marseille, France; jean-francois.landrier@univ-amu.fr

* Correspondence: joanna.suliburska@up.poznan.pl

**Abstract:** Obesity has been linked to vitamin D (VD) deficiency and low calcium (CAL) status. In the last decade, dietary supplementation of vitamin D and calcium (VD–CAL) have been extensively studied in animal experiments and human studies. However, the physiological mechanisms remain unknown as to whether the VD–CAL axis improves homeostasis and reduces biomarkers in regulating obesity and other metabolic diseases directly or indirectly. This review sought to investigate their connections. This topic was examined in scientific databases such as Web of Science, Scopus, and PubMed from 2011 to 2021, and 87 articles were generated for interpretation. Mechanistically, VD–CAL regulates from the organs to the blood, influencing insulin, lipids, hormone, cell, and inflammatory functions in obesity and its comorbidities, such as non-alcoholic fatty liver disease, cardiovascular disease, and type-2 diabetes mellitus. Nevertheless, previous research has not consistently shown that simultaneous VD–CAL supplementation affects weight loss or reduces fat content. This discrepancy may be influenced by population age and diversity, ethnicity, and geographical location, and also by degree of obesity and applied doses. Therefore, a larger prospective cohort and randomised trials are needed to determine the exact role of VD–CAL and their interrelationship.

**Keywords:** vitamin D; calcium; obesity; physiology; comorbid

**1. Introduction**

Due to inappropriate diets and nutrient intake, obesity has become more common in all age groups, such as children [1], adolescents [2], and the elderly [3]. Obesity is increasing in prevalence in Asia-Pacific [4], Europe [5], Africa [6], and America [7] and has become a worldwide epidemic [8]. Taking this into account, the member states of the United Nations have developed a global platform, the Sustainable Development Goals, addressing noncommunicable diseases as core priorities [9].

Obesity is caused by micronutrient deficiency [10], inadequate intake of vitamins, such as cobalamin (vitamin B12), ascorbic acid (vitamin C), fat-soluble vitamins, and folic acid [11], a deficiency of vitamin D (VD) [12], poor mineral status [13], and low calcium (CAL) diet [14]. The average plasma concentration of 25(OH)D is used to determine VD level. A less than 50 nmol/L of 25(OH)D serum concentration indicates VD deficiency. [15]. Furthermore, obesity is characterised by accumulation of >70% of body fat mass [16]. VD$_3$, and its metabolites 25(OH)D$_3$ and 1,25(OH)$_2$D$_3$, are deposited in adipocyte lipid droplets [17]. 25(OH)D is a fat-soluble metabolite disseminated to fat, muscle, liver, and in smaller amounts to other tissues. The stomach’s ability to absorb CAL depends on the presence of active VD. VD deficiency causes osteomalacia and rickets in adults and children, respectively, whereas moderate deficiency results in an upsurge in the risk of bone turnover and bone fractures [12].

On the other hand, CAL ion (Ca$^{2+}$) is available in abundance in the body. Ca$^{2+}$ is deposited in bones, mostly as CaPO$_3$ (hydroxyapatite), and plays a structural role. It
is required for muscle contraction and pancreatic secretion of insulin and glucagon in response to blood glucose fluctuations. Therefore, alterations in Ca\(^{2+}\) homeostasis can have a strong impact on tissues, including the heart and skeletal muscle, contributing to obesity and diabetes [18]. The adipocyte metabolism pathway is regulated by intracellular Ca\(^{2+}\). In human adipocytes, intracellular Ca\(^{2+}\) stimulates energy and fat storage through de novo lipogenesis (DNL) promotion and lipolysis prevention [19]. Hypocalcemia is characterized by CAL concentrations under 8 mg/dL or ionized CAL levels under 4.4 mg/dL [20].

Numerous experiments have established a link between vitamin D and calcium (VD–CAL) supplementation and the occurrence of metabolic diseases [21] such as chronic liver disease [22], osteoporosis [23], diabetes mellitus [24], and high blood pressure [25]. However, there are some discrepancies in the results, and the role of VD–CAL supplementation remains unclear [26]. Contradictory outcomes have been reported for VD levels [27] and CAL status [28] in obesity. Furthermore, an expert panel concluded that no confirmation supports the extraskeletal role of CAL or VD [29].

In light of current knowledge, this study assessed the interrelationship of VD–CAL in the onset of obesity and its comorbid conditions using scientific evidence from recent animal studies and human clinical trials. Besides that, this study also collected the relationship of VD–CAL in the metabolic functions of obesity, such as in the gut, bone, blood lipid and glucose levels, kidney, pancreas, liver, adipose tissue, and the immunoregulatory system. This review could aid in developing dietary recommendations for obese people and future studies into the influences of VD–CAL simultaneous supplementation in this group.

2. Search Strategy and Method

Scientific databases, such as Web of Science, Scopus, and PubMed, were utilised to conduct a methodical search for relevant articles by employing the following key phrases: “correlation”, “relationship”, “link”, “association”, “vitamin-D”, “calcium”, “obesity”, “rats”, “mice”, and “human clinical trial”. The search generated 87 articles published between 2011 and 2021, which investigated the relationship of VD–CAL in obesity (Figure 1). Table 1 shows the inclusion and exclusion criteria for this literature search strategy. Duplicates, review articles, protocol studies, second analysis reports, articles not related to VD–CAL, and articles not published in English were excluded. The interrelationship findings were compiled by summarising them in tables.

![Flowchart of identifying, screening, selecting, and determining the literature search.](image-url)
Table 1. Search constraints and criteria.

| Constraint          | Inclusion                                                                 | Exclusion                                                                 |
|---------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Type of articles    | Scientific articles on animal experiments and human investigations        | In vitro assessment                                                       |
| Relationship        | Studies related to the association of either VD, CAL, or both in obese    | Studies not related to the association of either VD, CAL, or both in obese |
| Comparator          | Placebo or no comparator                                                  | —                                                                         |
| Outcomes            | There was scientific evidence of the association of either VD, CAL, or both with obesity | There was no scientific evidence of the association of either VD, CAL, or both with obesity |
| Study design        | Evidence-based interventions, including multi-level factors, types of action, outcomes, and unintended negative consequences | Repetition articles, review journals, protocol records, case studies, second analysis reports, inadequate explanation of VD–CAL, neglect of English language, and issued earlier than 2011 |

VD: vitamin D; CAL: calcium; —: not to be defined.

3. Physiological Association of VD–CAL

Figure 2 depicts the role of the VD–CAL axis in regulating the physiological mechanisms involved in obesity. VD–CAL status determines adipose tissue functions, body fatness, bone density, inflammatory, insulin, hormone, and cell functions.

![Figure 2. The regulation of vitamin D-calcium axis in obesity.](image-url)
VD exists naturally in a limited number of food sources and is endogenously formed when solar ultraviolet rays (290–315 nm) stimulate VD synthesis in the body’s outermost layer and is then primarily kept in fat in the body [30].

The available evidence indicates that VD–CAL is involved in physiological interactions; 1,25(OH)2D, an active VD metabolite, regulates CAL transport across the intestinal wall and binds to the VD receptor (VDR) in the intestinal epithelial cells, inducing the synthesis of CAL-binding protein CaBP-9K and activating TRPV6 and TRPV5 CAL channels. CAL enters the cell through the intestinal lumen and is transported by CAL-binding protein throughout the cell and to the interstitium via an ATP-dependent mechanism [31]. In the intestinal epithelium, 1,25(OH)2-D modulates paracellular CAL channels in the transepithelial electrochemical gradient by regulating claudin-2 and claudin-12 [32]. In adipose tissue, it stimulates voltage-dependent and voltage-insensitive Ca2+ access pathways and controls Ca2+ release from endoplasmic reticulum stores via inositol 1,4,5-triphosphate and ryanodine receptors [16]. In bone regulation, 1,25(OH)2D enters cells by diffusion by binding to complex VDRs and regulates mineralised bone mass by controlling intestinal CAL absorption and supplying adequate CAL to the bone matrix [33,34]. In beta cells, activated VD metabolites increase the sensitivity of insulin receptors, glucose homeostasis transcription factors, and/or CAL regulation in peripheral insulin-target cells [30,35]. CAL in the extracellular fluid stimulates CaSR on the parathyroid cells, which raises intracellular CAL levels and suppresses PTH release. In the kidneys, PTH regulates the conversion of 25(OH)D to 1,25(OH)2D, which augments intestinal CAL absorption. PTH has the ability to administer circulating IL-6 and TNF-α concentrations, which promote the production of high-sensitivity C-reactive protein [32,36].

4. Interrelationship of VD–CAL in Obesity and Its Disease States

4.1. Impact of VD–CAL on Adipose Tissue

The accumulation of a large amount of fat in adipose tissue characterises obesity. The relationship between VD–CAL and obesity, both with and without supplementation, is shown in Table 2.

Table 2. VD–CAL in adipose tissues in animal and human studies.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| Animal study |                     |                   |               |                 |
| [37]       | Male C57BL/6J wild-type mice aged eight weeks old | A high-fat diet with 500 IU/kg diet followed by a 10,000 IU/kg diet of VD₃ | Obesity | Gut and adipose tissue cross-talked in VDRs signalling associated with lipid homeostasis. |
| [38]       | C57BL/6 mice aged six weeks old | High-fat diet with 25,000 IU of VD₃ | Obesity | ↑ VD₃ concentrations in liver and adipose tissue |
| [39]       | Male C57BL/6 mice aged six weeks old | High-fat and high-sucrose with 15,000 IU/kg of VD | Obesity | ↓ chemokine mRNA concentrations in adipose tissue; ↓ lipid droplets and triglyceride accumulation in the liver; ↓ hepatic DNL and fatty acid oxidation expression. |
| [40]       | New-born Wistar rats | 1 µg/kg of 1,25(OH)₂D₃ | Obesity | ↓ macrophages in pancreas and adipose tissue infiltration; ↑ Tgf-β1 in liver tissue expression; ↑ Treg cells and insulin-targeted tissues infiltration. |
| [41]       | Obese C57BL/6J mice aged five weeks old | A high-fat diet with 4 g/kg of CAL | Obesity | ↓ endotoxin concentrations; ↑ angiopeptin-like 4 expression; ↓ hepatic lipid; ↑ adipose tissue expression and inflammation. |
Table 2. Cont.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [42]      | Obese Wistar rats   | 10 g CaCO₃/kg     | Obesity       | ↓ VAT fat acid synthase, ↓ leptinemia; and ↓ Vdr. |
| [43]      | Early weaning Wistar rats | 10 g CaCO₃/kg | Obesity       | ↑ calbindin, VDR and prevented adipose tissue dysfunction |
| [44]      | Four-week-old C57BL/6J male mice | High CAL, high VD | Obesity | ↓ weight gain (body and fat), ↑ adiposity and ↑ plasma glucose, insulin, adiponectin, calcifediol, calcitriol, PTH. |
| [45]      | Obese male Wistar rats with CAL deficiency | 1000 mg of CAL carbonate per 100 g high-fat diet | Obesity | ↓ body weight, ↓ adiposity, ↓ glucose, ↓ insulin, ↓ HOMA-IR, ↓ TNF-α, IL-6, MCP-1, Leptin, ↓ hepatic lipid, ↓ hepatic macrophage, ↓ adipocyte hypertrophy, and ↑ adiponectin level |

**Human study**

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [46]      | Obese adolescent patients aged 14.1 ± 2.8 years old | 4000 IU of VD₃ | Obesity | ↑ serum 25(OH)D; ↑ fasting insulin; ↑ HOMA-IR; ↑ leptin-to-adiponectin ratio; No changes in inflammatory signs. |
| [47]      | Men and women with overweight and obese aged 18–65 years old | 350 mg of CAL and 100 IU of VD₃ | Obesity | Significant correlation of VD–CAL on visceral adipose tissue. |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.

Adipose tissue stores most of VD, which influences CAL homeostasis and energy metabolism. A link has been shown between VD levels and CAL in adipose tissue. In obese individuals, supplementation with VD causes a significant accumulation of this vitamin in the liver and adipose tissue [38], increased leptin-to-adiponectin ratio [46], and decreased inflammation in adipose tissue [37] and hepatic steatosis by downregulating the gene expression associated with hepatic de novo lipogenesis (DNL) and oxidation of fatty acid [39]. It was also shown that administration of a high-fat diet supplemented with 1,25(OH)₂D₃ resulted in a reduction in macrophage infiltration in adipose tissue [40].

Besides VD intervention, supplementation of CAL in obese people was found to confer a prebiotic-like effect on the gut microbiota and decrease the stress marker expression in adipose tissue and liver inflammation [41], reduce body mass and modify glucocorticoid receptors expression and Vdr in the visceral adipose tissue [42], increase the expression of Cyp27b1/1α-hydroxylase and adipogenesis [43], decrease adipocyte hypertrophy and adipokines levels (TNF-α, IL-6, MCP-1, leptin), and rise adiponectin levels [45].

Supplementation of VD and CAL may be a useful and cost-efficient strategy for preventing and treating obesity. Rosenblum et al. [47] reported that a serving of 350 mg CAL and 100 IU VD per 240 mL glasses of orange juice resulted in significant depletion of visceral adipose tissue. Similarly, Sergeev and Song [44] observed that a high intake of VD–CAL influenced the adipose tissue Ca²⁺-mediated apoptotic pathway. The authors noted that VD₃–CAL supplementation was more potent than either of these alone in decreasing adiposity in male C57BL/6J mice aged four weeks old.

4.2. Impact of VD–CAL on Body Fatness

Obesity is commonly linked to a lack of VD–CAL, which are nutrients that regulate body fat. The relationship between these nutrients and obesity is summarised in Table 3.
### Table 3. VD–CAL in body fatness.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| **Animal Study** | | | | |
| [48] | Obese male C57BL/6 mice aged twenty four weeks old | 162 IU, 1282 IU and 5169 IU of VD₃/kg | Obesity | ↓ serum calcitriol; ↑ serum parathyroid hormone. |
| [49] | Male C57BL/6 mice aged ten weeks old | A high-fat diet with VD-enriched mushrooms extract | Obesity | ↓ total body fat; ↓ hepatic fat content; ↑ immunomodulatory effect (CD4/CD8 lymphocyte ratio). |
| [50] | Wistar and genetically predisposed obese IIMb/b rats | A low dose of 0.2% CaCO₃ | Obesity | ↑ body fat, ↑ liver weight, ↑ perigonadal and retroperitoneal fat in low CAL intake; ↓ body ashes and ↓ total skeleton bone mineral in low CAL intake. |
| [51] | Male C57BL/6 mice aged five weeks old | A high-fat diet | Obesity | ↓ CYP2R1 and CYP27A1, CYP27B1, VDR; ↑ CYP24A1 (24-hydroxylase); ↑ DNA methylation, Dnmt activity, and 5-methylcytosine; ↓ Tet activity and 5-hydroxymethylcytosine. |
| [52] | C57BL/6 mice | A high-fat diet | Obesity | ↓ Cyp2r1 mRNA; Positive relationship between Cyp2r1 mRNA levels with 25(OH)D levels and cholecalciferol ratio. |
| **Human Study** | | | | |
| [53] | Type 2 diabetes patients aged 30–60 years old | Fortified yogurt drink by 170 mg CAL with 12.5 µg VD₃/250 mL twice a day | Diabetic type 2 | ↓ waist circumference, ↓ fat mass, ↓ truncal fat, and ↓ visceral adipose tissue. |
| [54] | Healthy overweight or obese women with an average age of 38 ± 8.1 years old | Cholecalciferol 25 µg | Obesity | ↓ serum iPTH levels; ↓ fat mass; No alterations in body weight and waist circumference. |
| [55] | Healthy adults aged 18–50 years old with BMI > 30 kg/m² | 7000 IU of VD each day | Obesity | No alterations in body fat, intramyocellular lipids, VAT, intrahepatic, subcutaneous, HOMA, blood pressure, plasma lipids, and hsCRP. |
| [56] | Males and females aged 35–51 years old with BMI ≥ 30 kg/m² | No intervention of VD | Obesity | Negative correlation among 25(OH)D levels, BMI, and percentage body fat. |
| [57] | Thin and obese women aged 57–90 years old with VD insufficiency (50 nmol/L) | Daily doses of VD₃ of 400, 800, 1600, 2400, 3200, 4000, and 4800 IU | Obesity | No significantly different in total body fat mass. |
| [58] | Obese women aged 18–48 years old | 50,000 IU of cholecalciferol/week, 1200 mg/dl CAL/day, and cholecalciferol plus CAL | Obesity | ↓ body fat percentage, ↓ fasting blood glucose, ↓ PTH, ↓ cholesterol, and ↓ triglycerides in cholecalciferol plus CAL intake. |
| [59] | Overweight or obese male aged 18–25 years old | CAL carbonate (600 mg) and VD₃ (125 IU) | Obesity | ↓ fat mass loss; ↓ visceral fat mass and ↓ visceral fat area. |
| [60] | Overweight and obese males and females aged greater than 65 years old | 600 IU and 3750 IU of VD | Obesity | No significant differences in muscle and visceral adiposity. |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.
The prevalence of obesity may be decreased by a dose of VD or CAL. Evidence suggests that VD–CAL intake can decline body fat. The higher the concentration of 25(OH)D, the lower the body fat mass [54]. Similar to VD, a low CAL intake can negatively impact the levels of various lipid metabolic markers (glucose, triglyceride, and insulin) and increase body fat [50]. BMI and body fat levels strongly correlate with 25(OH)D concentration and the CAL-phosphorus product [56]. A high-fat diet has been revealed to promote hypermethylation and hypomethylation of Cyp24a1, resulting in glutathione deficiency and an altered VD biosynthesis pathway [51]. Additionally, there was a correlation between decreased Cyp2r1 gene expression and decreased circulating 25(OH)D concentrations [52].

However, VD–CAL levels in obese people have an unsatisfactory correlation. In obese individuals, neither BMI nor body fat percentage were significantly related to VD levels [48]. After treatment, no impact of VD supplementation was obtained on body fat, subcutaneous and visceral adipose tissue, and intrahepatic and intramyocellular lipids in this population [55]. Additionally, VD supplementation had no discernible effect on total body fat mass [57]. These results support the most recent finding that weekly VD₃ administration at a high dose (3750 IU) had no impact on sarcopenia or adiposity indices [60].

VD–CAL have been gaining increasing interest in obesity management. These nutrients have been tested in combination and also formulated in food products. A VD-enriched Lentinula edodes preparation reduced total body fat accumulation and hepatic fat content in obese C57BL/6 mice [49]. Similarly, a study showed that consumption of VD-fortified yoghurt drink (containing 170 mg CAL and 12.5 μg VD₃/250 mL) for twelve weeks led to a decrease in waist circumference, body fat mass, and truncal fat in people with type-2 diabetes aged 30–60 years old [53]. In addition, supplementation of CAL and VD₃ caused a significant reduction in weight, BMI, waist circumference, and body fat percentage in obese women aged 18–48 years old [58]. In another study on overweight or obese males aged 18–25 years old, a 12-week supplementation of CAL and VD₃ (600 mg of CAL and 125 IU of VD₃) resulted in body fat loss and visceral fat loss [59].

4.3. Impact of VD on Bone Density

Patients and healthcare practitioners frequently overlook the importance of VD in bone health. Table 4 presents the findings of studies on the advantageous effects of VD.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [61]      | C57BL/6j male and female offspring | High and low VD | Obesity | Positive correlation between Bacteroides and LPS, trabecular femur peak load, vertebral trabecular separation, trabecular number, and bone volume fraction in both |
| [62]      | Three-week-old C57BL/6j mice | High or low VD; high fat and sucrose | Obesity | ↓ lower intestinal permeability; ↑ trabecular number and ↓ trabecular separation; No effects on IL-6 and TNF-α serum concentrations. |
| [63]      | Twenty-one-week-old male obese Sprague Dawley rats underwent Roux-en-Y gastric bypass | High-fat diet | Obesity | ↓ serum bicarbonate, calcium, 25-hydroxyvitamin D, insulin, and leptin levels; ↑ serum osteocalcin; ↓ P1NP levels; ↓ the volume, number, and thickness of trabecular bone. |
| [64]      | Male C57BL/6N obese mice aged five weeks old | High-fat diet | Obesity | ↓ Il12b mRNA levels in stimulated bone marrow-derived dendritic cells |
| [65]      | Female C57BL/6j mice aged eight months old | Saturated fatty acids and VD 1000 IU/kg diet | Obesity | ↓ hepatic Cyp2r1 and renal Cyp24a1 mRNA expression |
Diet-induced obesity has been found to decrease the volume, number, and thickness of trabecular bone [63]. Diets containing saturated fatty acids and adequate amount of VD altered the metabolism of VD and bone changes, which suggests the critical role of dietary fat composition [65]. Supplementation of VD increased intestinal permeability and systemic lipopolysaccharide levels, resulting in stronger trabecular bone [61,62], and inhibited differentiation and maturation [64], as well as elevated autophagy flux of bone marrow-derived dendritic cells [66]. Furthermore, VD levels have been linked with bone loss [67], bone turnover [68], and areal bone mineral density [69].

### 4.4. Impact of VD–CAL on Inflammatory, Insulin, Hormone, and Cell Functions

Obesity and its associated health problems are linked to low levels of VD–CAL in the blood. VD–CAL contributes to obesity and its comorbidities by influencing inflammation, insulin sensitivity, hormone production, and cell functions (Table 5).

#### Table 4. Cont.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [66]      | C57BL/6 males aged ten weeks old | High-fat diet, VD 1000 and 10,000 IU/kg diet | Obesity | ↓ phenotypes related to dendritic cells function expression; ↓ production of IL-12p70 by bone marrow-derived dendritic cells; ↑ LC3 II/I and VPS34 protein concentrations; ↓ p62 expression; ↓ Vdr mRNA levels. |
| [67]      | Healthy overweight and obese women | VD: doses (100,000 IU; 3420 IU; and 3420 IU) | Obesity | ↓ BMD; ↑ bone turnover markers; normal parathyroid hormone concentrations; No association between weight loss and changes in BMD; Positive association between low levels of bone loss and high levels of 25(OH)D. |
| [68]      | Healthy males and females aged 18–50 years old | 7000 IU cholecalciferol | Obesity | ↑ plasma 25OHD, ↓ PTH, ↓ CTX; Inverse correlation between alterations in plasma 25(OH)D, bone-specific alkaline phosphatase, and CTX; Inverse correlation between alterations in CTX and in spine BMD; Association between ↑ levels of 25OHD with ↓ PTH, ↓ bone turnover, and ↑ BMD at the forearm. |
| [69]      | Overweight and obese children aged 8–11 years old | No intervention of VD | Obesity | A link between 25(OH)D and areal BMD. |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.

#### Table 5. VD–CAL in inflammatory, insulin, hormone, and cell functions.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| Animal study |                     |                   |               |                 |
| [70]      | Male BALB/C mice | A high-fat diet | Obesity | ↑ cytokine levels and IL-1b mRNA expression; Negative correlation between VD levels, inflammatory cells, IL-1b and IL-17 levels. |
| [71]      | Male Wistar rats | A high-fat diet | Obesity | ↓ intracellular CAL transient rates, ↓ rates and amplitude of salivary acinar cells |
Table 5. Cont.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [72]      | Males C57BL/6 mice aged five weeks old | Diet-induced obesity | Obesity | ↓ autophagy of T cells, ↑ dysregulation of T cell homeostasis |
| [73]      | Male Wistar rats | VD 500 IU/kg diet | Obesity | ↓ food intake and weight gain; ↓ hippocampus acetylcholine concentrations; ↑ hippocampus IL-6 concentrations. |
| [74]      | Male Wistar rats | VD 500 IU/kg diet | Obesity | ↓ weight and food intake; ↓ insulin resistance; No influence of VD on degenerated neurons and TNF-α concentration. |
| [75]      | Hippocampus male Wistar rats | VD 500 IU/kg diet | Obesity | ↓ body weight, NF-κB concentrations, blood–brain barrier permeability; ↑ increased brain-derived neurotrophic factor concentrations. |
| [76]      | Male C57BL/6 mice aged five weeks old | VD 10,000 IU/kg diet | Obesity | ↓ natural killer cells |
| [77]      | C57BL/6J mice | A high-fat/high-sugar diet with low amounts of VD | Obesity | ↓ steatosis and fibrosis; ↓ inflammatory and pro-fibrotic genes; ↓ intestinal inflammation. |
| [78]      | Male C57BL/6J mice aged four weeks old | A high fat-high sugar with VD | Obesity | ↓ NF-κB activation, TNF-alpha level, SCAP/SREBP lipogenic pathway activation, CML protein adducts level, and RAGE expression. |
| [79]      | Male C57BL/6N mice aged ten weeks old | A high-fat diet with 1000 or 10,000 IU of VD/kg diet | Obesity | ↑ CD4 + IL-17 + T cells; ↑ CD4 + CD25 + Foxp3 + T cells; ↓ phospho-p70S6K/total-p70S6K ratio; ↑ phospho-AKT/total-AKT ratio; ↓ Hif1α mRNA levels. |
| [80]      | Obesity-related diabetes rats | VD | Obesity | ↓ parathormone and adipocytokines |
| [81]      | Obese male Wistar rats | 500 IU/kg VD | Obesity | ↑ superoxide dismutase activity; ↓ catalase activity; ↓ TNF-α concentration in heart tissue. |
| [82]      | Obese male Wistar rats | 500 IU/kg VD | Obesity | ↓ glutathione peroxidase activity; ↓ hepatic tumour necrosis factor concentrations; ↑ superoxide dismutase activity; No effects on glutathione peroxidase or catalase activity. |
| [83]      | Female Wistar rats | 10 g CaCO₃/kg diet | Obesity | ↑ fatty acid synthase, ↑ steatosis, and ↓ protein kinase B (Akt) |
| [84]      | Men and women aged 30–80 years old | 1000, 2000, and 4000 IU VD₃ per day | Obesity | ↓ PTH levels with 1000 IU per day; ↑ PTH levels with 2000 to 4000 IU per day. |
| [85]      | Patients aged 20–60 years old | A high-CAL diet (1200–1300 mg/d) and low-CAL diet (<500 mg/d) | Obesity | ↓ inflammation markers, ↓ fibrinolysis, and ↓ endothelial dysfunction. |
### Table 5. Cont.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [86]      | Males and females aged 18–59 years old | 50,000 IU of VD per week | Obesity | ↓ PTH, MCP-1, IL-1β and TLR-4 |
| [87]      | Obese and overweight women aged 20–40 years old | 50,000 IU VD per week | Obesity | No alterations in C-reactive protein, insulin, insulin resistance, and waist to hip ratio. |
| [88]      | Overweight and obese adults (aged 32 ± 8.5 years old) | Cholecalciferol doses 100,000 IU followed by 4000 IU per day | Obesity | No influence in iPTH and cFGF-23; Inverse correlations between serum iPTH and cFGF-23. |
| [89]      | Obese children and adolescents aged 12.89 ± 1.63 years old | VD 120,000 IU/month and 12,000 IU/month | Obesity | No significant difference in insulin resistance, sensitivity, inflammatory cytokines, and pulse wave velocity |
| [90]      | Pregnant women | 400 IU/d to 150,000 IU per three months | Obesity | Positive association: BMI and 9 inflammatory biomarkers; Positive association: BMI and sICAM-1, hs-CRP, and AGP; Inverse association: 25(OH)D and sICAM-1, hs-CRP, and AGP; No impact of VD intake on inflammatory biomarkers. |
| [91]      | Overweight and obese youth aged 11–17.99 years old | 150,000 IU ergocalciferol per 3 months | Obesity | No alteration in inflammatory markers |
| [92]      | Obese patients aged between 10 and 65 years | No intervention of VD | Obesity | ↓ blood levels of VD; ↑ US-CRP, IL-6, HOMA |
| [93]      | Obese patients aged >18 years old | No intervention of VD | Obesity | ↓ metabolic status, ↑ liver enzymes, ↑ inflammatory markers |
| [94]      | Healthy children aged 9–13 years old | No intervention of VD | Obesity | ↑ VD insufficiency occurrence in children with IR |
| [95]      | Obese adolescents aged 12.7 ± 1.3 years old | No intervention of VD | Obesity | Negative association: 25(OH)D and HOMA-IR with alanine aminotransferase |
| [96]      | Obese and overweight postmenopausal women without diabetes | No intervention of VD | Obesity | Inverse association: 25(OH)D and fasting and 2-h insulin, HOMA-IR, and PTH |
| [97]      | Overweight and obese children aged 2-18-year-old | No intervention of vitamin D | Obesity | ↓ serum 25(OH) D level; ↓ PTH |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.

Apart from its vital role in CAL homeostasis, VD–CAL is involved in modulating inflammatory, insulin, hormone, and cell functions in obesity. Administration of VD was shown to reduce intestinal inflammation [77] and the level of inflammatory markers [82,83,94], and also regulate the concentrations of IL-1β, NF-Kβ, acetylcholine, brain-derived neurotropic factor [73], blood-brain barrier permeability [75], and pro-inflammatory cytokine levels [70]. However, previous studies suggest that VD–CAL supplementation does not affect inflammatory regulation in obesity. VD intervention did not cause any change in the concentrations of us-CRP and IL-6 [92], sICAM-1, hs-CRP, AGP [90], and inflammatory cytokines [89,91]. Similarly, a study showed that a CAL-rich diet had no beneficial impact on inflammation, fibrinolysis, and endothelial function [85].
Furthermore, a high-fat diet triggered insulin resistance [71], and VD deficiency also correlated with this condition in obese people [94]. VD intake influenced IRS-1/p-IRS-1 expression [80] and enhanced HOMA-IR [74]. CAL intake also improved insulin sensitivity, redox balance, and liver steatosis [83]. Nevertheless, VD supplementation had a negative impact on the relationship between 25(OH)D and insulin resistance [95] and HOMA-IR [87,96].

VD has been linked to cell regulation in obesity. The intake of this vitamin was shown to inhibit the expression of NF-κB [78] and regulate HIF1α in T cells [79]. However, VD intake had no significant effect on IFN-γ intracellular expression, NKG2D, and CD107a surface expression in NK cells, Vdup1 and Vdr mRNA levels [76], and T cell autophagy [72]. Apart from its role in inflammatory, insulin, and cell functions, a connection has been found between VD and hormone regulation, with VD exerting a suppressing effect on PTH levels in obese individuals [84,86,88,97].

4.5. Potential Applications of VD–CAL in Obesity Prevention

Low levels of VD–CAL have been connected with an improved risk of obesity. Supplementation of VD–CAL can be beneficial in the treatment of obesity, as summarised in Table 6.

Table 6. The evidence of VD–CAL supplementation in obesity.

| Reference  | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|------------|---------------------|-------------------|---------------|-----------------|
|            | Animal study        |                   |               |                 |
| [98]       | Male C57BL/6j mice  | High-fat/sucrose  | Obesity       | ↑ insulin sensitivity and hepatic steatosis in combining physical exercise and VD; ↓ hepatic de novo lipogenesis in combining physical exercise and VD. |
|            | aged ten weeks old  | (HFS), physical   |               |                 |
|            |                     | exercise, and VD  |               |                 |
| [99]       | Adult Wistar strain | Monosodium glutamate | Obesity     | ↓ body weight, food, and water intake |
|            | albino female rats  | and calcitriol    |               |                 |
| [100]      | Male C57BL/6j mice  | VD₃ 15,000 IU/kg diet | Obesity     | ↑ lipid oxidation; ↑ upregulation of fatty acid oxidation and mitochondrial metabolism genes; ↑ expenditure on energy. |
|            | aged six weeks old  |                   |               |                 |
| [101]      | Male C57BL/6N mice  | VD 1000 and       | Obesity       | ↑ colonic ClDN1 and Cyp27b1 mRNA levels; Negative relationship: 25(OH)D levels and histology score. |
|            | aged five weeks old | 10,000 IU/kg diet |               |                 |
| [102]      | Male Sprague Dawley | 50 mg/kg coral CAL | Obesity       | ↓ body weight gain, ↑ hepatic mitochondrial dysfunction, ↓ oxidative stress, and activated phase II enzymes in coral CAL hydride treatment. |
|            | rats aged six weeks | and 50 mg/kg coral |               |                 |
|            | old with high-fat-diet-induced | CAL hydride |               |                 |
|            | NAFLD                |                   |               |                 |
| [103]      | Low-density lipoprotein | Salmon peptide fraction | Obesity     | ↑ metabolic syndrome via a gut-liver axis ↑ Mglabacterium and Muribaculaceae |
|            | receptor (LDLr) mice | and VD₃ (15,000 IU/kg of diet) |           |                 |
| [104]      | Overweight and obese | 400 IU of VD per day | Obesity       | An association weight loss and ↑ 25(OH)D levels. |
|            | women                |                   |               |                 |
| [105]      | Overweight and obese | 400 IU of VD per day | Obesity       | ↑ 25(OH)D; ↓ PTH; Inverse relationship between 25(OH)D and waist-to-hip ratio. |
|            | adults aged 26.1 ± 4.7|                   |               |                 |
|            | years old with a BMI |                   |               |                 |
|            | 31.3 ± 3.2 kg/m²    |                   |               |                 |
| [106]      | Overweight or obese  | 500–600 mg/day CAL, | Obesity       | ↓ weight and BMI in all interventions |
|            | premenopausal women  | 800 mg/day CAL,   |               |                 |
|            | aged 20–50 years old | low-fat milk (1.5%), and |           |                 |
|            |                      | soy milk fortified CAL |           |                 |
|            |                      | 1200 and 1300 mg/day |           |                 |
### Table 6. Cont.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| [107]     | Overweight and obese patients | 4000 IU of VD per day with exercise training | Obesity | A significant correlation between percent body fat and CRP; and serum 25OHD and CRP; A significant reduction in unstimulated TNFα production both groups. |
| [108]     | Adults aged 30–50 years old with abdominal obesity | Fortified low-fat yogurt (1500 IU VD₃ per 150 g/d); fortified low-fat milk (1500 IU VD₃ per 200 g/d) | Obesity | ↑ 25(OH)D serum levels; ↓ weight to hip ratio; ↑ triglyceride and HDL-C ↓ fasting serum insulin ↑ HOMA-IR and quantitative insulin sensitivity |
| [109]     | Obese adolescents aged 12–17 years old and with BMI 31.2–36.2 kg/m² | Fruit juice with VD 4000 IU per day | Obesity | ↑ total and free 25(OH)D; ↓ HOMA-IR and CRP; ↑ endothelium-dependent microvascular. |
| [110]     | Overweight, obese patients aged 18–60 years old | 4000 IU cholecalciferol/day | NAFLD and NASH with VD-deficient | No impact between VD and hepatic enzymes |
| [111]     | Obese, pre-menopausal adult women | 75,000 IU cholecalciferol | Cardiovascular with VD-deficient | ↑ activity of neutral sphingomyelinas, ↓ chylomicrons, ↓ LDL and VLDL, ↓ postprandial inflammation and endothelial macrophage adhesion |
| [112]     | Overweight and obese African Americans aged 57.0 ± 10.4 years old | VD₃ (4000 IU/day) | Prediabetes with VD-deficient | ↑ 25(OH)D level; No impact of VD on post-load glucose or other glycemic measures. |
| [113]     | Obese male veterans aged 35–85 years old | 50,000 IU ergocalciferol/week | Prediabetes with 25(OH)D level 5.0–29 ng/mL | ↑ left atrial volume ergocalciferol, No significant difference in blood pressure and other diastolic parameters |
| [114]     | Diabetic patients aged 66.3 ± 4.4 years old | 30,000 IU cholecalciferol/week | Type 2 diabetes with VD deficient or insufficient | ↓ hs-CRP and TNF-α concentrations |
| [115]     | Male and female 30–40-year-olds with obesity and type 2 diabetes | Stage 1: 6000 IU of VD/day; Stage 2: 3000 IU of VD/day; Stage 3: 2200 IU of VD/day | Obesity and type 2 diabetes | No associations between VD supplementation with weight, fat mass, or waist circumference |
| [116]     | Obese males and females aged 18–70 years old | Cholecalciferol 25,000 IU/week | Obesity with VD deficient | ↑ insulin sensitivity |
| [117]     | Obese children aged 2–14 years old | Cholecalciferol 50,000 IU/day | Obesity with VD deficiency | ↑ VD deficiency status after consuming the dose of cholecalciferol |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.

Obesity and its related conditions have been studied in relation to VD’s potential role as a treatment. Supplementing with VD lowered the rate of weight gain [99] and body mass [104], increased glucose homeostasis, and regulated energy expenditure in obese people [100]. Additionally, VD intake prevented histological damage of the colon [101], reduced hepatic steatosis, improved mitochondrial dysfunction in the liver, decreased stress oxidation, and triggered phase II enzymes [102].

Clinical studies, on the other hand, have found no link between 25(OH)D concentrations and hepatic enzymes, indicating a lack of interaction between VD deficiency and obesity [110] and no impact of VD on post-load glucose or other glycemic indices [112]. Supplementing with VD had no significant effect on weight, fat mass, or waist circumference [115]. Lack of VD increased the activity of neutral sphingomyelinas in obese people with cardiovascular disease, which had implications for chylomicron and low-density lipoprotein (LDL) and very-low-density lipoprotein clearance, as well as decreased postprandial inflammation and macrophage adhesion to endothelia [111].
On the other hand, in obese patients with VD deficiency, VD supplementation significantly enhanced serum 25(OH)D levels [117], reduced the size of the left atrium [113], reduced hs-CRP and TNF-α concentrations [114], and increased insulin sensitivity [116]. Furthermore, VD intake combined with physical exercise led to a rise in peak power and VD status, reduced waist-to-hip ratio [104], and improved insulin resistance and hepatic disease [98]. However, this combination did not influence inflammatory biomarkers such as CRP, TNF-α, and IL-6 [107].

The role of diets enriched with VD–CAL has also been investigated. Faghih et al. [106] reported that diet of a daily 500 kcal deficit with daily 500–600 mg CAL (1), a daily 500 kcal deficit with daily 800 mg CAL (2), a daily 500 kcal deficit with three servings of low-fat milk (3), and a daily 500 kcal deficit with three portions of CAL-fortified soy milk (4), resulted in decreased body weight and BMI in all groups of healthy, overweight, or obese premenopausal women aged 20–50 years. Valle et al. [103] showed that supplementation of salmon peptide fraction (25% of protein) and VD (15,000 IU/kg of diet) aided in maintaining metabolic syndrome via gut–liver axis by controlling hepatic and gut inflammation (increasing Mogibacterium and Muribaculaceae) in mice fed with high-fat and high-sucrose diets containing VD (25 IU/kg of diet). Sharifan et al. [108] observed a correlation between fortified dairy products containing VD₃ (1500 IU) and anthropometric indices, glucose homeostasis, and lipid profiles in adults (30–50 years old) with abdominal obesity. Similarly, Vinet et al. [109] observed that consumption of 200 mL fruit juice supplemented with VD₃ (4000 IU) every morning led to the weakening of microvascular dysfunction without any impact on macrovascular function by increasing 25(OH)D levels, decreasing HOMA-IR and CRP, and improving endothelium-dependent microvascular reactivity in obese adolescents aged 12–17 years old and with a BMI of 31.2–36.2 kg/m².

Unfortunately, prior studies could not identify a compensatory mechanism and did not exhibit the impact of VD–CAL channels, namely TRPV5 and TRPV6, which can influence the CAL transport process. According to Veldurthy et al. [118], 1,25(OH)₂D₃ regulated transcellular transport by influencing the epithelial CAL channel TRPV5. TRPV5 enables the entry of apical CAL entry by inducing calbindins (calbindin-D₉k and calbindin-D₂₈k). Moreover, calbindin-D₉k and TRPV6 expression are administered by 1,25(OH)₂D₃. TRPV6 overexpression results in hypercalciuria, hypercalcemia, and calcification of soft tissues, indicating that this channel plays a key role in the intestinal absorption of CAL.

4.6. Inadequate Evidence for the Effect of VD–CAL on Obesity

Although the benefits of VD–CAL supplementation have been documented, previous reports have established that these two nutrients are incompatible. The inconsistent results about the impacts of VD–CAL observed in experiments on obese populations are summarised in Table 7.

Thomas et al. [119] demonstrated insufficient evidence for the influence of high dietary CAL (CAL carbonate) on obesity-related phenotypes, including impaired weight gain and hyperphagia, in diet-induced obese 4-week-old male C57BL/6j mice. Wood et al. [120] found no effect on physical function after VD₃ supplementation (400 or 1000 IU) for one year in postmenopausal women aged 60–70 years old with a BMI of 18–45 kg/m². Salehpour et al. [121] presented inadequate data on the impact of VD₃ intake (25 µg as cholecalciferol) on glucose homeostasis in overweight or obese women with an average age of 38 ± 8 years old and a BMI of 29.9 ± 4.2 kg/m². Brzezinski et al. [122] observed an insignificant impact of 26-week VD (1200 IU) intake on body weight reduction in overweight and obese children aged 6–15 years old who had VD insufficiency (<30 ng/mL). Additionally, Jones et al. [123] showed that supplementation of dairy (~700 mg per day of CAL with 500 kcal per day) and CAL-rich dairy (~1400 mg per day of CAL with 500 kcal per day) had no effect in increasing weight loss. However, CAL-rich dairy improved plasma levels of peptide tyrosine tyrosine in men and women aged 20–60 years old and with a BMI of 27–37 kg/m². Kerkvliet et al. [124] demonstrated that the supplementation with VD–CAL did not significantly affect the alteration of body composition in overweight postmenopausal women.
Table 7. The inadequate evidence of VD–CAL status in obesity.

| Reference | Experimental Design | Diet Intervention | Comorbidities | Highlight Result |
|-----------|---------------------|-------------------|---------------|-----------------|
| Animal study | | | | |
| [119] | Obese male C57BL/6J mice aged four weeks old | A high-fat diet, high-CAL, and high-CAL + non-fat dry milk | Obesity | ↓ body weight and adiposity; ↑ adiposity in high-CAL diet; ↑ feed efficiency and hyperphagia develop obesity in high-Ca mice; A strong correlation between mRNA markers of macrophages. |
| Human study | | | | |
| [120] | Healthy post-menopausal women aged 60–70 years old | 400 and 1000 IU of VD₃ | Obesity | No improvement in physical function (grip strength or falls) |
| [121] | Overweight and obese women aged 38 ± 8 years old with a BMI 29.9 ± 4.2 kg/m² | 25 µg of VD₃ | Obesity | ↓ fasting blood glucose concentrations; ↑ 25(OH)D concentrations; ↓ percentage of HbA1c; Significant association: HbA1c and 25(OH)D concentrations. |
| [122] | Overweight and obese children aged 6–15 years old | 1200 IU of VD₃ | Obesity | ↓ BMI not significant; ↓ fat mass not significant; No impact on body weight reduction |
| [123] | Men and women aged 20–60 years old with a BMI 27–37 kg/m² | Dairy with 700 mg/day CAL, and 1400 mg/day CAL | Obesity | ↑ weight loss and ↑ plasma levels of peptide tyrosine tyrosine (PYY) in high CAL fortification. |
| [124] | Overweight females with postmenopausal aged around 51.3 years old | Daily 800 mg of CAL citrate and malate + 400 IU of VD | Overweight with postmenopausal | Negligible impact on body composition |

VD: vitamin D; CAL: calcium; ↑: increase; ↓: decrease.

Based on the literature review, it can be concluded that the role of CAL and VD in metabolic disorders and obesity is well understood. However, the results on the impact of the deficit or the supplementation used on body weight, fat content, or biochemical parameters obtained especially in human studies are often ambiguous. It seems that many factors, including population diversity, may lead to the inconsistency of results of VD–CAL in the obese. The cited studies were conducted on a variety of populations, geographies, and races. For instance, low VD status affects the occurrence of a VD deficiency in Western European residents during the wintertime periods, South Africa, Oceania, and Asian countries (Middle East, China, Mongolia, and India) [125]. In the same vein as the global VD status, many countries have low average dietary CAL ranges between 175 and 1233 mg across half the world’s nations, such as Asia, Africa, and Latin America, and only a handful of European countries [126]. Furthermore, low VD concentrations were discovered to be a significant difference between native residents with immigrant residents [127] and multi-ethnic residents [128]. Besides that, there was an association between VD levels and elevation in a population [129]. A difference of one or two degrees in latitude enormously influenced 25(OH)D serum levels and bone density amid a low VD-sufficiency population [130]. Two different continents in the same population also influenced the CAL concentrations [131]. Therefore, these variables may predominance the inadequate evidence of VD–CAL supplementation in obese populations [120–124].

5. Limitations

Overall, the evidence from previous studies showing the importance of the VD–CAL axis in obesity suggests that investigations carried out so far, especially human studies,
could not find a clear relationship between VD–CAL status in obesity [120–124]. There is also data showing harmful effects caused by consuming these nutrients alone or in combination [132]. However, prior studies on animal models [98–103] and humans largely [104–117] recommend the use of VD–CAL as potential therapeutic agents for the management of obesity.

Using a comprehensive literature strategy, this article has presented results collected from the studies conducted in the last ten years on the interrelationship of VD–CAL in obesity. However, the present article also has some limitations, including the lack of discussion about the side effects of VD–CAL intake, including its toxicity, which can be helpful for designing an obesity management therapy. It should be mentioned that CAL intervention studies have provided minimal evidence [133,134] supporting the application of CAL supplements in treating obesity and its comorbidities.

6. Conclusions and Perspectives

There is little research into the effects of the concomitant use of VD and CAL on obesity and metabolic disorders. The results of the current research, where VD and CAL were used separately and in combination, are inconclusive. Mechanistically, the VD–CAL axis affects lipid status, insulin, hormones, cells, and inflammatory functions in obesity and its comorbidities from the organs to the blood. Previous research on animals and humans has not consistently supported the hypothesis that VD–CAL supplementation can accelerate weight loss or fat loss in obesity. Many factors may affect the obtained results, including the age of subjects, degree of obesity, applied doses, population diversity, ethnicity, and geographical location. Therefore, more large-scale prospective cohort studies and randomised trials are required to fully clarify the simultaneous administration of VD–CAL as well as their interrelationship for the safe use of these nutrients in the management of the global obesity epidemic.

Author Contributions: Conceptualisation, I.A.H. and J.S.; methodology, I.A.H.; data curation, I.A.H.; writing—original draft preparation, I.A.H. and J.S.; writing—review and editing, I.A.H., J.-F.L. and J.S.; visualisation, I.A.H.; funding acquisition, J.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study secured the statutory research from Poznan University of Life Sciences with No. 506-786-00-03.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Conflicts of Interest: The authors state no conflict of interest.

References
1. Kumar, S.; Kelly, A.S. Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment. Mayo Clin. Proc. 2017, 92, 251–265. [CrossRef] [PubMed]
2. de Souza Silva, J.; Sobrinho, S.; Elaine Pereira, S.; José Saboya Sobrinho, C.; Ramalho, A. Nutrición Hospitalaria Trabajo Original Obesidad, enfermedades relacionadas y su relación con la deficiencia de vitamina D en adolescentes. Nutr. Hosp. 2016, 33, 856–864.
3. Dădărlat-Pop, A.; Sitar-Tăut, A.; Zdrenghea, D.; Caloian, B.; Tomoaia, R.; Pop, D.; Buzoianu, A. Profile of obesity and comorbidities in elderly patients with heart failure. Clin. Interv. Aging 2020, 15, 547–556. [CrossRef] [PubMed]
4. Khoo, S.; Morris, T. Physical activity and obesity research in the Asia-Pacific: A review. Asia-Pac. J. Public Health 2012, 24, 435–449. [CrossRef] [PubMed]
5. Pineda, E.; Sanchez-Romero, L.M.; Brown, M.; Jaccard, A.; Jewell, J.; Galea, G.; Webber, L.; Breda, J. Forecasting Future Trends in Obesity across Europe: The Value of Improving Surveillance. Obes. Facts 2018, 11, 360–371. [CrossRef] [PubMed]
6. Yako, Y.Y.; Echouffo-Tcheugui, J.B.; Balti, E.V.; Matsha, T.E.; Sobngwi, E.; Erasmus, R.T.; Kengne, A.P. Genetic association studies of obesity in Africa: A systematic review. Obes. Rev. 2015, 16, 259–272. [CrossRef] [PubMed]
7. Rosenthal, R.J.; Morton, J.; Brethauer, S.; Mattar, S.; De Maria, E.; Benz, J.K.; Titus, J.; Sterrett, D. Obesity in America. Surg. Obes. Relat. Dis. 2017, 13, 1643–1650. [CrossRef] [PubMed]
8. Jaacks, L.M.; Vandevijvere, S.; Pan, A.; McGowan, C.J.; Wallace, C.; Imamura, F.; Mozaffarian, D.; Swinburn, B.; Ezzati, M. The obesity transition: Stages of the global epidemic. *Lancet Diabetes Endocrinol.* 2019, 7, 231–240. [CrossRef]

9. Castro, L.N.; Jewell, J.; Whiting, S.; Rippin, H.; Farrand, C.; Wickramasinghe; Kremlin Breda, J. *Nutrition, Overweight and Obesity Factsheet-Sustainable Development Goals: Health Targets*; World Health Organization: Geneva, Switzerland, 2021.

10. Damms-Machado, A.; Weser, G.; Bischoff, S.C. Micronutrient deficiency in obese subjects undergoing low calorie diet. *Nutr. J.* 2012, 11, 34. [CrossRef]

11. Thomas-Valdés, S.; Das, M.; Tostes, G.V.; Anunciação, P.C.; Da Silva, B.P.; Sant’ana, H.M.P.; Thomas-Vald Es, S.; Das Graças, M.; Tostes, V.; Anunciação, P.C.; et al. Association between vitamin deficiency and metabolic disorders related to obesity. *Crit. Rev. Food Sci. Nutr.* 2017, 57, 3332–3343. [CrossRef]

12. Walsh, J.S.; Bowles, S.; Evans, A.L. Vitamin D in obesity. *Curr. Opin. Endocrinol. Diabetes Obes.* 2017, 24, 389–394. [CrossRef]

13. Suliburska, J.; Cofta, S.; Gajewska, E.; Kalmus, G.; Sobieska, M.; Samborski, W.; Krejpcio, Z. The evaluation of selected serum mineral concentrations and their association with insulin resistance in obese adolescents. *Eur. Rev. Med. Pharmacol. Sci.* 2013, 17, 2396–2400.

14. Marotte, C.; Bryk, G.; Gonzales Chaves, M.M.S.; Lifshitz, F.; Pita Martín de Portela, M.L.; Zeni, S.N. Low dietary calcium and obesity: A comparative study in genetically obese and normal rats during early growth. *Eur. J. Nutr.* 2014, 53, 769–778. [CrossRef]

15. Pereira-Santos, M.; Costa, P.R.F.; Assis, A.M.O.; Santos, C.A.S.T.; Santos, D.B. Obesity and vitamin D deficiency: A systematic review and meta-analysis. *Obes. Rev.* 2016, 17, 341–349. [CrossRef]

16. Song, Q.; Sergeev, I.N. Calcium and vitamin D in obesity. *Nutr. Res. Rev.* 2012, 25, 130–141. [CrossRef]

17. Heaney, R.P.; Recker, R.R.; Grote, J.; Horst, R.L.; Armas, L.A.G. Vitamin D(3) is more potent than vitamin D(2) in humans. *J. Clin. Endocrinol. Metab.* 2011, 96, E447–E452. [CrossRef]

18. Arteh, J.; Narra, S.; Nair, S. Prevalence of vitamin D deficiency in chronic liver disease. *Indian J. Clin. Biochem.* 2011, 26, 381–397. [CrossRef]

19. Zemel, M.B.; Thompson, W.; Milstead, A.; Morris, K.; Campbell, P. Calcium and dairy acceleration of weight gain and fat loss during energy restriction in obese adults. *Obes. Res.* 2004, 12, 582–590. [CrossRef]

20. Vuralli, D. Clinical Approach to Hypocalcemia in Newborn Period and Infancy: Who Should Be Treated? *Int. J. Pediatr.* 2019, 2019, 4318075. [CrossRef]

21. Muñoz-Garach, A.; García-Fontana, B.; Muñoz-Torres, M. Vitamin D status, calcium intake and risk of developing type 2 diabetes: An unresolved issue. *Nutrients* 2019, 11, 642. [CrossRef]

22. Arteh, J.; Narra, S.; Nair, S. Prevalence of vitamin D deficiency in chronic liver disease. *Dig. Dis. Sci.* 2010, 55, 2624–2628. [CrossRef]

23. Weaver, C.M.; Alexander, D.D.; Boushey, C.J.; Dawson-Hughes, B.; Lappe, J.M.; LeBoff, M.S.; Liu, S.; Looker, A.C.; Wallace, T.C.; Wang, D.D. Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation. *Osteoporos. Int.* 2016, 27, 367–376. [CrossRef]

24. Mitri, J.; Dawson-Hughes, B.; Hu, F.B.; Pittas, A.G. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: The Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. *Am. J. Clin. Nutr.* 2011, 94, 486–494. [CrossRef]

25. Goel, R.K.; Lal, H. Role of Vitamin D Supplementation in Hypertension. *Indian J. Clin. Biochem.* 2011, 26, 88–90. [CrossRef]

26. Vranic, L.; Mikolašević, I.; Milić, S. Vitamin D deficiency: Consequence or cause of obesity? *Eur. J. Nutr.* 2014, 55, 541. [CrossRef]

27. Duan, L.; Han, L.; Liu, Q.; Zhao, Y.; Wang, L.; Wang, Y. Effects of Vitamin D Supplementation on General and Central Obesity: Results from 20 Randomized Controlled Trials Involving Apparently Healthy Populations. *Ann. Nutr. Metab.* 2020, 76, 153–164. [CrossRef]

28. Lu, L.; Chen, C.; Tang, W.; Jacobs, D.; Shikany, J.; He, K. Calcium Intake Is Inversely Related to the Risk of Obesity among American Young Adults over a 30-Year Follow-Up. *Curr. Dev. Nutr.* 2020, 4, 1445. [CrossRef]

29. Panu, P.K.; Calton, E.K.; Soares, M.J. *Calcium and Vitamin D in Obesity and Related Chronic Disease*, 1st ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2016; Volume 77.

30. El-Hajj Fuleihan, G. Can the sunshine vitamin melt the fat? *Metabolism* 2012, 61, 603–610. [CrossRef]

31. Lips, P. Interaction between Vitamin D and calcium. *Scurd. J. Clin. Lab. Investig.* 2012, 72, 60–64. [CrossRef]

32. Goltzman, D.; Mannstadt, M.; Marcocci, C. Physiology of the Calcium-Parathyroid Hormone-Vitamin D Axis. In *Vitamin D in Clinical Medicine*; Karger: Basel, Switzerland, 2018; Volume 50, pp. 1–13. [CrossRef]

33. Pérez-López, F.R.; Chedraui, P.; Fernández-Alonso, A.M. Vitamin D and aging: Beyond calcium and bone metabolism. *Maturitas* 2011, 69, 27–36. [CrossRef]

34. Carmeliet, G.; Dermawu, V.; Bouillon, R. Vitamin D signaling in calcium and bone homeostasis: A delicate balance. *Best Pract. Res. Clin. Endocrinol. Metab.* 2015, 29, 621–631. [CrossRef] [PubMed]

35. Tabesh, M.; Azadbakht, L.; Faghihimani, E.; Tabesh, M.; Esmailzadeh, A. Effects of calcium–vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: A randomised controlled clinical trial. *Diabetologia* 2014, 57, 2038–2047. [CrossRef] [PubMed]

36. Tabesh, M.; Azadbakht, L.; Faghihimani, E.; Tabesh, M.; Esmailzadeh, A. Calcium-vitamin D co-supplementation influences circulating inflammatory biomarkers and adipokynes in vitamin D-insufficient diabetics: A randomized controlled clinical trial. *J. Clin. Endocrinol. Metab.* 2014, 99, E2485–E2493. [CrossRef] [PubMed]
37. Jahn, D.; Dorbath, D.; Schilling, A.K.; Gildein, L.; Meier, C.; Vuille-dit-Bille, R.N.; Schmitt, J.; Kraus, D.; Fleet, J.C.; Hermanns, H.M.; et al. Intestinal vitamin D receptor modulates lipid metabolism, adipose tissue inflammation and liver steatosis in obese mice. Biochim. Biophys. Acta—Mol. Basis Dis. 2019, 1865, 1567–1578. [CrossRef]

38. Park, C.Y.; Shin, Y.; Kim, J.H.; Zhu, S.; Jung, Y.S.; Han, S.N. Effects of high fat diet-induced obesity on vitamin D metabolism and tissue distribution in vitamin D deficient or supplemented mice. Nutr. Metab. 2020, 17, 44. [CrossRef]

39. Marziou, A.; Philouze, C.; Couturier, C.; Astier, J.; Obert, P.; Landriar, J.F.; Riva, C. Vitamin d supplementation improves adipose tissue inflammation and reduces hepatic steatosis in obese c57bl/6 mice. Nutrients 2020, 12, 342. [CrossRef]

40. Jin, W.; Cui, B.; Li, P.; Hua, F.; Lv, X.; Zhou, J.; Hu, Z.; Zhang, X. 1,25-Dihydroxyvitamin D3 protects obese rats from metabolic syndrome via promoting regulatory T cell-mediated resolution of inflammation. Acta Pharm. Sin. B 2018, 8, 178–187. [CrossRef]

41. Chaplin, A.; Parra, P.; Laraichi, S.; Serra, F.; Palou, A. Calcium supplementation modulates gut microbiota in a prebiotic manner in dietary obese mice. Mol. Nutr. Food Res. 2016, 60, 468–480. [CrossRef]

42. Conceição, E.P.S.; Moura, E.G.; Manhaes, A.C.; Carvalho, J.C.; Nobre, J.L.; Oliveira, E.; Lisboa, P.C. Calcium reduces vitamin D and glucocorticoid receptors in the visceral fat of obese male rats. J. Endocrinol. 2016, 230, 263–274. [CrossRef]

43. Nobre, J.L.; Lisboa, P.C.; Peixoto-Silva, N.; Quitete, F.T.; Carvalho, J.C.; de Moura, E.G.; de Oliveira, E. Role of vitamin D in adipose tissue in obese rats programmed by early weaning and post diet calcium. Mol. Nutr. Food Res. 2016, 60, 810–822. [CrossRef]

44. Sergeev, I.N.; Song, Q. High vitamin D and calcium intakes reduce diet-induced obesity in mice by increasing adipose tissue apoptosis. Mol. Nutr. Food Res. 2014, 58, 1342–1348. [CrossRef]

45. Das, S.; Choudhuri, D. Dietary calcium regulates the insulin sensitivity by altering the adipokine secretion in high fat diet induced obese rats. Life Sci. 2020, 250, 117560. [CrossRef]

46. Belenchia, A.M.; Tosh, A.K.; Hillman, L.S.; Peterson, C.A. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: A randomized controlled trial. World Rev. Nutr. Diet. 2014, 109, 18–19. [CrossRef]

47. Rosenblum, J.L.; Castro, V.M.; Moore, C.E.; Kaplan, L.M. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am. J. Clin. Nutr. 2012, 95, 101–108. [CrossRef]

48. Seldeen, K.L.; Pang, M.; Rodriguez-Gonzalez, M.; Hernandez, M.; Sheridan, Z.; Yu, P.; Troen, B.R. A mouse model of vitamin D insufficiency: Is there a relationship between 25(OH) Vitamin D levels and obesity? Nutr. Metab. 2017, 14, 26. [CrossRef]

49. Drori, A.; Rotnemer-Golinkin, D.; Avni, S.; Drori, A.; Danay, O.; Levanon, D.; Tam, J.; Zolotarev, L.; Ilan, Y. Attenuation of the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift. BMC Gastroenterol. 2017, 17, 130. [CrossRef]

50. Marotte, C.; Weissstaub, A.; Bryk, G.; Olguin, M.C.; Posadas, M.; Lucero, D.; Schreier, L.; Pita Martínez De Portela, M.L.; Zeni, S.N. Effect of dietary calcium (Ca) on body composition and Ca metabolism during growth in genetically obese (β) male rats. Eur. J. Nutr. 2013, 52, 297–305. [CrossRef]

51. Parsanathan, R.; Jain, S.K. Glutathione deficiency induces epigenetic alterations of vitamin D metabolism genes in the livers of high-fat diet-fed obese mice. Sci. Rep. 2019, 9, 14784. [CrossRef]

52. Roizen, J.D.; Long, C.; Casella, A.; O’Lear, L.; Caplan, I.; Lai, M.; Sasson, I.; Singh, R.; Makowski, A.J.; Simmons, R.; et al. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. J. Bone Miner. Res. 2019, 34, 1068–1073. [CrossRef]

53. Shab-Bidar, S.; Neyestani, T.R.; Djazayery, A. Vitamin D receptor Cdx-2-dependent response of central obesity to Vitamin D intake in the subjects with type 2 diabetes: A randomized clinical trial. Br. J. Nutr. 2013, 114, 1375–1384. [CrossRef]

54. Salehpour, A.; Hosseinzanah, F.; Shidfar, F.; Vafa, M.; Razaghi, M.; Dehghani, S.; Hoshiarrad, A.; Gohari, M.A. A 12-week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women. Nutr. J. 2012, 11, 78. [CrossRef]

55. Wamberg, L.; Kampmann, U.; Stødkilde-Jørgensen, H.; Rejmark, L.; Pedersen, S.B.; Richelsen, B. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels—Results from a randomized trial. Eur. J. Intern. Med. 2013, 24, 644–649. [CrossRef]

56. Jabbour, J.; Rahme, M.; Mahfoud, Z.R.; El-Hajj Fuleihan, G. Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: A randomized controlled trial. Endocrine 2022, 76, 162–171. [CrossRef]
61. Villa, C.R.; Taibi, A.; Chen, J.; Ward, W.E.; Comelli, E.M. Colonic Bacteroides are positively associated with trabecular bone structure and programmed by maternal Vitamin D in male but not female offspring in an obesogenic environment. *Int. J. Obes.* 2018, 42, 696–703. [CrossRef] [PubMed]

62. Villa, C.R.; Chen, J.; Wen, B.; Sacco, S.M.; Taibi, A.; Ward, W.E.; Comelli, E.M. Maternal Vitamin D beneficially programs metabolic, gut and bone health of mouse male offspring in an obesogenic environment. *Int. J. Obes.* 2016, 40, 1875–1883. [CrossRef] [PubMed]

63. Canales, B.K.; Schafer, A.L.; Shoback, D.M.; Carpenter, T.O. Gastric bypass in obese rats causes bone loss, vitamin D deficiency, metabolic acidosis, and elevated peptide YY. *Surg. Obes. Relat. Dis.* 2014, 10, 878–884. [CrossRef] [PubMed]

64. Cha, K.S.; Park, C.Y.; Lee, S.E.; Kim, T.Y.; Han, S.N. The effects of 1,25-dihydroxyvitamin D3 on markers related to the differentiation and maturation of bone marrow-derived dendritic cells from control and obese mice. *J. Nutr. Biochem.* 2020, 85, 108464. [CrossRef]

65. Wang, Y.; Buckendahl, P.; Sharma, K.; Miller, J.W.; Shapses, S.A. Expression of vitamin D hydroxylases and bone quality in obese mice consuming saturated or monounsaturated enriched high-fat diets. *Nutr. Res.* 2018, 60, 106–115. [CrossRef]

66. Kim, S.J.; Cho, D.H.; Lee, G.Y.; An, J.H.; Han, S.N. The effects of dietary vitamin D supplementation and in vitro 1,25 dihydroxyvitamin D3 treatment on autophagy in bone marrow-derived dendritic cells from high-fat diet-induced obese mice. *J. Nutr. Biochem.* 2021, 100, 108880. [CrossRef]

67. Luger, M.; Krutschitz, R.; Winzer, E.; Schindler, K.; Grabovac, I.; Kainberger, F.; Krebs, M.; Hoppichler, F.; Prager, G.; et al. Changes in Bone Mineral Density Following Weight Loss Induced by One-Anastomosis Gastric Bypass in Patients with Vitamin D Supplementation. *Obes. Surg.* 2018, 28, 3454–3465. [CrossRef]

68. Wamberg, L.; Pedersen, S.B.; Richelsen, B.; Rejnmark, L. The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin D: Results from a randomized controlled study. *Calcif. Tissue Int.* 2013, 93, 69–77. [CrossRef]

69. Gil-Cosano, J.J.; Gracia-Marco, L.; Ubago-Guisado, E.; Migueles, J.H.; Mora-Gonzalez, J.; Escolano-Margarit, M.V.; Gómez-Vida, J.; Maldonado, J.; Ortega, F.B. Muscular fitness mediates the association between 25-hydroxyvitamin D and areal bone mineral density in children with overweight/obesity. *Nutrients* 2019, 11, 2760. [CrossRef]

70. Zhang, J.H.; Chen, Y.P.; Yang, X.; Li, C.Q. Vitamin D3 levels and NLRP3 expression in murine models of obese asthma: Association with asthma outcomes. *Braz. J. Med. Biol. Res.* 2018, 51, e6841. [CrossRef]

71. Ittichaicharoen, J.; Apaijai, N.; Tanajak, P.; Sa-nguanmoo, P.; Chattipakorn, N.; Chattipakorn, S.C. Impaired Mitochondria and Intracellular Calcium Transients in the Salivary Glands of Obese Rats. *Appl. Physiol. Nutr. Metab.* 2016, 42, 420–429. [CrossRef]

72. Kang, M.S.; Park, C.Y.; Lee, G.Y.; Cho, D.H.; Kim, S.J.; Han, S.N. Effects of in vitro vitamin D treatment on function of T cells and autophagy mechanisms in high-fat diet-induced obese mice. *Nutr. Res. Pract.* 2021, 15, 673. [CrossRef]

73. Farhangi, M.A.; Mesgari-Abbasi, M.; Nameni, G.; Hajiluian, G.; Shahabi, P. The effects of vitamin D administration on brain inflammatory markers in high fat diet induced obese rats. *BMC Neurosci.* 2017, 18, 81. [CrossRef]

74. Nameni, G.; Hajiluian, G.; Shahabi, P.; Farhangi, M.A.; Mesgari-Abbasi, M.; Hemmati, M.R.; Vatandoust, S.M. The Impact of Vitamin D Supplementation on Neurodegeneration, TNF-α Concentration in Hypothalamus, and CSF-to-Plasma Ratio of Insulin in High-Fat-Diet-Induced Obese Rats. *J. Mol. Neurosci.* 2017, 61, 247–255. [CrossRef] [PubMed]

75. Hajiluian, G.; Nameni, G.; Shahabi, P.; Mesgari-Abbasi, M.; Sadigh-Eteghad, S.; Farhangi, M.A. Vitamin D administration, cognitive function, BPP permeability and neuroinflammatory factors in high-fat diet-induced obese rats. *Int. J. Obes.* 2017, 41, 639–644. [CrossRef] [PubMed]

76. Lee, G.Y.; Park, C.Y.; Cha, K.S.; Lee, S.E.; Pae, M.; Han, S.N. Differential effect of dietary vitamin D supplementation on natural killer cell activity in lean and obese mice. *J. Nutr. Biochem.* 2018, 55, 178–184. [CrossRef] [PubMed]

77. Jahn, D.; Dorbath, D.; Kircher, S.; Nier, A.; Bergheim, I.; Lienaerts, K.; Hermans, H.M.; Geier, A. Beneficial effects of vitamin D treatment in an obese mouse model of non-alcoholic steatohepatitis. *Nutrients* 2019, 11, 77. [CrossRef] [PubMed]

78. Benetti, E.; Mastrocola, R.; Chiazza, F.; Nigro, D.; D’Antona, G.; Bordano, V.; Fantozzi, R.; Aragno, M.; Collino, M.; Minetto, M.A. Effects of vitamin D on insulin resistance and myosteatosis in diet-induced obese mice. *PLoS ONE* 2018, 13, e0189707. [CrossRef] [PubMed]

79. An, J.H.; Cho, D.H.; Lee, G.Y.; Kang, M.S.; Kim, S.J.; Han, S.N. Effects of vitamin D supplementation on CD4+ T cell subsets and mTOR signaling pathway in high-fat-diet-induced obese mice. *Nutrients* 2021, 13, 796. [CrossRef] [PubMed]

80. Guo, Y.; Zhu, L.; Ge, Y.; Zhang, H. Improving effect of vitamin D supplementation on obesity-related diabetes in rats. *Minerva Endocrinol.* 2020, 45, 29–35. [CrossRef]

81. Farhangi, M.A.; Nameni, G.; Hajiluian, G.; Mesgari-Abbasi, M. Cardiac tissue oxidative stress and inflammation after vitamin D administrations in high fat diet-induced obese rats. *BMC Cardiovasc. Disord.* 2017, 17, 161. [CrossRef]

82. Farhangi, M.A.; Mesgari-Abbasi, M.; Shahabi, P. Hepatic Complications of High-Fat Diet-Induced Obesity: Reduction of Increased Hepatic Oxidative Stress and Tumor Necrosis Factor-Alfa Concentration by Vitamin D Administration. *Curr. Top. Nutraceutical Res.* 2020, 18, 360–365. [CrossRef]
102. Hou, C.; Wang, Y.; Zhu, E.; Yan, C.; Zhao, L.; Wang, X.; Qiu, Y.; Shen, H.; Sun, X.; Feng, Z.; et al. Coral calcium hydride prevents
100. Marcotorchino, J.; Tourniaire, F.; Astier, J.; Karkeni, E.; Canault, M.; Amiot, M.J.; Bendahan, D.; Bernard, M.; Martin, J.C.;
88. Mesinovic, J.; Mousa, A.; Wilson, K.; Scragg, R.; Plebanski, M.; de Courten, M.; Scott, D.; Naderpoor, N.; de Courten, B. Effect of
99. Nandan, P.; Nayanatara, A.K.; Poojary, R.; Bhagyalakshmi, K.; Nirupama, M.; Kini, R.D. Protective Role of Co-administration of
94. Moschonis, G.; Androutsos, O.; Hulshof, T.; Dracopoulou, M.; Chrousos, G.P.; Manios, Y. Vitamin D insufficiency is associated
93. Esteghamati, A.; Aryan, Z.; Esteghamati, A.; Nakhjavani, M. Differences in vitamin D concentration between metabolically healthy
obese adults: Associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes Metab. 2014, 40, 347–355. [CrossRef] [PubMed]
91. Shah, S.; Wilson, D.M.; Bachrach, L.K. Large doses of vitamin D fail to increase 25-hydroxyvitamin D levels or to alter cardiovascular
risk factors in obese adolescent students: A pilot study. J. Adolesc. Health 2015, 57, 19–23. [CrossRef]
90. Palaniswamy, S.; Gill, D.; De Silva, N.N.; Lowry, E.; Jokelainen, J.; Karhu, T.; Mutt, S.J.; Dehghan, A.; Sliz, E.; Chasman, D.I.; et al. Could Vitamin D reduce obesity-Associated inflammation? Observational and Mendelian randomization study. Am. J. Clin. Nutr. 2020, 111, 1036–1047. [CrossRef]
89. Varshney, S.; Khadigawat, R.; Gahlot, M.; Khandelwal, D.; Oberoi, A.; Yadav, R.; Sreenivas, V.; Gupta, N.; Tandon, N. Effect of high-dose Vitamin D supplementation on beta cell function in obese Asian-Indian children and adolescents: A randomized, double blind, active controlled study. Indian J. Endocrinol. Metab. 2019, 23, 545–551. [CrossRef]
88. Khosravi, Z.; Kafeshani, M.; Tavasoli, P.; Zadeh, A.; Entezari, M. Effect of Vitamin D supplementation on weight loss, glycemic
indices, and lipid profile in obese and overweight women: A clinical trial study. Int. J. Prev. Med. 2018, 9, 63. [CrossRef]
87. Lotfi-Dizaji, L.; Mahboob, S.; Alishafrasi, S.; Vaghef-Mehrabany, E.; Ebrahimi-Mameghani, M.; Morovati, A. Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: A double-blind placebo-controlled randomized clinical trial. Clin. Endocrinol. 2019, 90, 94–101. [CrossRef]
86. Kim, H.; Chandler, P.; Ng, K.; Manson, J.E.; Giovannucci, E. Obesity and efficacy of vitamin D3 supplementation in healthy black
adults. Cancer Causes Control. 2020, 31, 303–307. [CrossRef]
85. Torres, M.R.S.G.; Sanjuliiana, A.F. Effects of weight loss from a high-calcaium energy-reduced diet on biomarkers of inflammatory stress, fibrinolysis, and endothelial function in obese subjects. Nutrition 2013, 29, 143–151. [CrossRef]
84. Kim, H.; Chandler, P.; Ng, K.; Manson, J.E.; Giovannucci, E. Obesity and efficacy of vitamin D3 supplementation in healthy black
adults. Cancer Causes Control. 2020, 31, 303–307. [CrossRef]
106. Faghih, S.H.; Abadi, A.R.; Hedayati, M.; Kimiagar, S.M. Comparison of the effects of cows’ milk, fortified soy milk, and calcium supplement on weight and fat loss in premenopausal overweight and obese women. *Nutr. Metab. Cardiovasc. Dis.* 2011, 21, 499–503. [CrossRef]

107. Carrillo, A.E.; Flynn, M.G.; Pinkston, C.; Markofski, M.M.; Jiang, Y.; Donkin, S.S.; Teegarden, D. Vitamin D supplementation during exercise training does not alter inflammatory biomarkers in overweight and obese subjects. *Eur. J. Appl. Physiol.* 2012, 112, 3045–3052. [CrossRef] [PubMed]

108. Sharifan, P.; Ziaee, A.; Darroudi, S.; Rezaie, M.; Safarian, M.; Esiami, S.; Khadem-Rezaiyan, M.; Tayefi, M.; Mohammadi Bagiran, M.; Ghazizadeh, H.; et al. Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D3 on cardiometabolic indicators in adults with abdominal obesity: A total blinded randomized controlled trial. *Curr. Med. Res. Opin.* 2021, 37, 579–588. [CrossRef] [PubMed]

109. Vinet, A.; Morrissey, C.; Perez-Martin, A.; Goncalves, A.; Raverdy, C.; Masson, D.; Gayrard, S.; Carrere, M.; Landrier, J.F.; Amiot, M.J. Effect of vitamin D supplementation on microvascular reactivity in obese adolescents: A randomized controlled trial. *Nutr. Metab. Cardiovasc. Dis.* 2021, 31, 2474–2483. [CrossRef] [PubMed]

110. Naderpoor, N.; Mousa, A.; de Courten, M.; Scragg, R.; de Courten, B. The relationship between 25-hydroxyvitamin D concentration and liver enzymes in overweight or obese adults: Cross-sectional and interventional outcomes. *J. Steroid Biochem. Mol. Biol.* 2018, 177, 193–199. [CrossRef]

111. Fernández-Arroyo, S.; Hernández-Aguilera, A.; de Vries, M.A.; Burggraaf, B.; van der Zwan, E.; Pουw, N.; Joven, J.; Cabezas, M.C. Effect of vitamin D3 on the postprandial lipid profile in obese patients: A non-targeted lipidomics study. *Nutrients* 2019, 11, 1194. [CrossRef]

112. Harris, S.S.; Pittas, A.G.; Palermo, N.J. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. *Diabetes Obes. Metab.* 2012, 14, 789–794. [CrossRef]

113. Chacko, S.J.; Pauwaa, S.; Barendgols, E.; Ciubotaru, I.; Kansal, M.M. Vitamin D attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes. *Echocardiography* 2016, 33, 681–689. [CrossRef]

114. El Hajj, C.; Walrand, S.; Helou, M.; Yammine, K. Effect of Vitamin D Supplementation on Inflammatory Markers in Non-Obese Lebanese Patients with Type 2 Diabetes: A Randomized Controlled Trial. *Nutrients* 2020, 12, 2033. [CrossRef]

115. Chen, L.; Dong, Y.; Bhagatwala, J.; Raed, A.; Huang, Y.; Zhu, H. Vitamin D3 Supplementation Increases Long-Chain Ceramide Levels in Overweight/Obese African Americans: A Post-Hoc Analysis of a Randomized Controlled Trial. *Nutrients* 2020, 12, 981. [CrossRef]

116. Cefalo, C.M.A.; Conte, C.; Sorice, G.P.; Moffa, S.; Sun, V.A.; Cinti, F.; Salomone, E.; Muscogiuri, G.; Brocchi, A.A.G.; Pontecorvi, A.; et al. Global dietary calcium intake among adults: A systematic review. *Eur. J. Clin. Nutr.* 2016, 193–199. [CrossRef]

117. Chacko, S.J.; Pauwaa, S.; Barendgols, E.; Ciubotaru, I.; Kansal, M.M. Vitamin D attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes. *Echocardiography* 2016, 33, 681–689. [CrossRef]

118. Veldurthy, V.; Wei, R.; Oz, L.; Dhawan, P.; Jeon, Y.H.; Christakos, S. Vitamin D and calcium homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled Trial. *Osteoporos. Int.* 2016, 27, 269–275. [CrossRef]

119. Brzeziński, M.; Jankowska, A.; Słomińska-Fraczek, M.; Metelska, P.; Wiśniewski, P.; Socha, P.; Szlagatys-Sidorkiewicz, A. Long-term effects of vitamin D supplementation in obese children during integrated weight-loss programme—A double blind randomized placebo-controlled trial. *Nutrients* 2020, 12, 1093. [CrossRef]

120. Wood, A.D.; Secombes, K.R.; Thies, F.; Acott, L.S.; Black, A.J.; Reid, D.M.; Mavroeidi, A.; Simpson, W.G.; Fraser, W.D.; et al. Effect of vitamin D3 on the postprandial lipid profile in obese patients: A non-targeted lipidomics study. *Nutrients* 2019, 11, 1194. [CrossRef]

121. Jones, K.W.; Eller, L.K.; Parnell, J.A.; Doyle-Baker, P.; Edwards, A.L.; Reimer, R.A. Effect of a dairy-and calcium-rich diet on weight loss and appetite during energy restriction in overweight and obese adults: A randomized trial. *Trop. Pediatr.* 2016, 62, 269–275. [CrossRef]

122. Brzeziński, M.; Jankowska, A.; Słomińska-Fraczek, M.; Metelska, P.; Wiśniewski, P.; Socha, P.; Szlagatys-Sidorkiewicz, A. Long-term effects of vitamin D supplementation in obese children during integrated weight-loss programme—A double blind randomized placebo-controlled trial. *Nutrients* 2020, 12, 1093. [CrossRef]

123. Balk, E.M.; Adam, G.P.; Langberg, V.N.; Earley, A.; Clark, P.; Ebeling, P.R.; Mithal, A.; Rizzoli, R.; Zerbini, C.A.F.; Pierro, D.D.; et al. Global dietary calcium intake among adults: A systematic review. *Osteoparos. Int.* 2017, 28, 3315–3324. [CrossRef]
127. Van Der Meer, I.M.; Middelkoop, B.J.C.; Boeke, A.J.P.; Lips, P. Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: An overview. Ostéoporos Int. 2011, 22, 1009–1021. [CrossRef]

128. Radhakishun, N.; van Vliet, M.; von Rosenstiel, I.; Weijer, O.; Diamant, M.; Beijnen, J.; Brandjes, D. High prevalence of vitamin D insufficiency/deficiency in Dutch multi-ethnic obese children. Eur. J. Pediatr. 2015, 174, 183–190. [CrossRef]

129. Guessous, I.; Dudler, V.; Glatz, N.; Theler, J.M.; Zoller, O.; Paccaud, F.; Burnier, M.; Bochud, M. Vitamin D levels and associated factors: A population-based study in Switzerland. Swiss Med. Wkly. 2012, 142, w13719. [CrossRef]

130. Yeum, K.J.; Song, B.C.; Joo, N.S. Impact of geographic location on vitamin D status and bone mineral density. Int. J. Environ. Res. Public Health 2016, 13, 184. [CrossRef]

131. De Lucia, F.; Minisola, S.; Romagnoli, E.; Pepe, J.; Cipriani, C.; Scillitani, A.; Parikh, N.; Rao, D.S. Effect of gender and geographic location on the expression of primary hyperparathyroidism. J. Endocrinol. Invest. 2013, 36, 123–126. [CrossRef]

132. Heravi, A.S.; Michos, E.D. Vitamin D and Calcium Supplements: Helpful, Harmful, or Neutral for Cardiovascular Risk? Methodist Debakey Cardiovasc. J. 2019, 15, 207–213. [CrossRef] [PubMed]

133. Silk, L.N.; Greene, D.A.; Baker, M.K. The effect of calcium or calcium and Vitamin D supplementation on bone mineral density in healthy males: A systematic review and meta-analysis. Int. J. Sport Nutr. Exerc. Metab. 2015, 25, 510–524. [CrossRef] [PubMed]

134. Omotayo, M.O.; Dickin, K.L.; O’Brien, K.O.; Neufeld, L.M.; De Regil, L.M.; Stoltzfus, R.J. Calcium supplementation to prevent preeclampsia: Translating guidelines into practice in low-income countries. Adv. Nutr. 2016, 7, 275–278. [CrossRef] [PubMed]